Regeneron Steps Up Amgen Patent Spat With New Suit
Regeneron Pharmaceuticals Inc. has asked a London court to invalidate two patents covering molecules used in cancer treatments owned by rival Amgen Inc., the latest claim in an ongoing IP battle...To view the full article, register now.
Already a subscriber? Click here to view full article